WMATA Advertisement Lease Space

Added: May 03, 2018 11:47 am 1198021

Notice of Intent to Sole Source - Advertisement Lease Space
The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price purchase order to OUTFRONT Media, 1325 Massachusetts Ave, NW, Ste 200, Washington DC 20005, in accordance with the authority under FAR Part 13.501(a). This procurement is being conducted under simplified acquisitions procedures in accordance with FAR Parts 12 and 13, including subpart 13.5. The NAICS code is 541890 -Other Services Related to Advertising.

The Food and Drug Administration (FDA), Office of Medical Products and Tobacco (OMPT), is requesting the purchase of advertising lease space on Washington Metropolitan Area Transit Authority (WMATA) properties for a period of 12 months. Rapid advances in the science and technology of human drug development and manufacturing require FDA's human drug review program staff to keep pace with scientific advances and apply innovative methods and techniques to the review of new therapies. OMPT has created a dedicated team charged with the continuous recruiting, staffing, and retention of scientific, technical and professional personnel to review new applications for human drugs. The OMPT team is conducting proactive outreach to source qualified candidates and conduct competitive recruiting campaigns to fill vacancies that require top scientific technical and professional talent. Part of this continuous outreach is an FDA Branding Campaign that includes advertising to an audience of commuting professionals through broad WMATA multimedia (paper, electronics and mobile) advertising on trains, buses and in individual stations. WMATA has confirmed that OUTFRONT Media is the sole source provider for the existing inventory of advertising space within the Washington Metropolitan Area Transit Authority Properties through June 30, 2019.

This notice is not a request for competitive quotes. However, any party that believes it is capable of meeting the requirements as stated herein may submit a written response, i.e. capability statement, which clearly supports and demonstrates its ability to perform the requirements. Any response shall be received by the response date and time of this notice. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.

Response Date: 10:00 a.m. ET on June 3, 2018. Responses must be emailed to Haritha Raja at haritha.raja@fda.hhs.gov.